metformin has been researched along with Sarcopenia in 12 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Sarcopenia: Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have recently demonstrated that the combined treatment between moderate exercise and metformin slows sarcopenia's onset by a mechanism that includes adipose reduction and REDOX regulation." | 8.02 | Metformin and tBHQ Treatment Combined with an Exercise Regime Prevents Osteosarcopenic Obesity in Middle-Aged Wistar Female Rats. ( Hernández-Álvarez, D; Königsberg, M; Lopéz-Cervantes, SP; López-Diazguerrero, NE; Luna-López, A; Mena-Montes, B; Pedraza-Vázquez, G; Sánchez-Garibay, C; Toledo-Pérez, R, 2021) |
| "We showed that being female and at an older age, lower educational level, and lower BMI were risk factors for sarcopenia in elderly T2DM and that metformin acted as a protective agent against sarcopenia in these patients." | 7.96 | Risk Factors for Sarcopenia in the Elderly with Type 2 Diabetes Mellitus and the Effect of Metformin. ( Cao, L; Chen, F; Huang, T; Liu, T; Ma, G; Wang, D; Wang, Y; Wei, Q; Xu, S; Zhao, Y, 2020) |
| "Resistance training may prevent and treat sarcopenia and physical frailty, but not everyone can or wants to exercise." | 7.11 | MET-PREVENT: metformin to improve physical performance in older people with sarcopenia and physical prefrailty/frailty - protocol for a double-blind, randomised controlled proof-of-concept trial. ( Bradley, P; Clegg, A; Connolly, S; Hancock, HC; Hiu, S; Marsay, L; McDonald, C; Rennie, KJ; Robertson, L; Sayer, AAP; Simms, L; Steel, AJ; Steves, CJ; Storey, B; von Zglinicki, T; Wason, J; Wilson, N; Witham, M, 2022) |
| " This is the first known metformin repurposing trial in non-diseased individuals, aimed specifically at the resistance exercise "non-responder" phenotype present in the aging population." | 5.24 | Metformin to Augment Strength Training Effective Response in Seniors (MASTERS): study protocol for a randomized controlled trial. ( Bamman, MM; Bush, HM; Kern, PA; Long, DE; Martz, JL; McGwin, G; Peck, BD; Peterson, CA; Tuggle, SC, 2017) |
| " We have recently demonstrated that the combined treatment between moderate exercise and metformin slows sarcopenia's onset by a mechanism that includes adipose reduction and REDOX regulation." | 4.02 | Metformin and tBHQ Treatment Combined with an Exercise Regime Prevents Osteosarcopenic Obesity in Middle-Aged Wistar Female Rats. ( Hernández-Álvarez, D; Königsberg, M; Lopéz-Cervantes, SP; López-Diazguerrero, NE; Luna-López, A; Mena-Montes, B; Pedraza-Vázquez, G; Sánchez-Garibay, C; Toledo-Pérez, R, 2021) |
| "We showed that being female and at an older age, lower educational level, and lower BMI were risk factors for sarcopenia in elderly T2DM and that metformin acted as a protective agent against sarcopenia in these patients." | 3.96 | Risk Factors for Sarcopenia in the Elderly with Type 2 Diabetes Mellitus and the Effect of Metformin. ( Cao, L; Chen, F; Huang, T; Liu, T; Ma, G; Wang, D; Wang, Y; Wei, Q; Xu, S; Zhao, Y, 2020) |
| "Resistance training may prevent and treat sarcopenia and physical frailty, but not everyone can or wants to exercise." | 3.11 | MET-PREVENT: metformin to improve physical performance in older people with sarcopenia and physical prefrailty/frailty - protocol for a double-blind, randomised controlled proof-of-concept trial. ( Bradley, P; Clegg, A; Connolly, S; Hancock, HC; Hiu, S; Marsay, L; McDonald, C; Rennie, KJ; Robertson, L; Sayer, AAP; Simms, L; Steel, AJ; Steves, CJ; Storey, B; von Zglinicki, T; Wason, J; Wilson, N; Witham, M, 2022) |
| "Drugs currently used to treat type 2 diabetes mellitus may have mechanisms of action that are relevant to the prevention and treatment of sarcopenia, for those with type 2 diabetes and those without diabetes." | 3.01 | Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia - A Narrative Review. ( Granic, A; Pearson, E; Robinson, SM; Sayer, AA; Witham, MD, 2023) |
| "Metformin is an AMPK agonist potentiating insulin actions in the adult human muscle, but not in the aged individuals." | 2.50 | Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. ( Cetrone, M; Mele, A; Tricarico, D, 2014) |
| "Sarcopenia is a geriatric syndrome and it impairs physical function." | 1.56 | A cross-sectional study: Associations between sarcopenia and clinical characteristics of patients with type 2 diabetes. ( Cui, M; Gang, X; Jiang, Z; Li, Z; Wang, G; Xiao, X, 2020) |
| " To date, there is great controversy if MTF treatment combined with exercise training improves or nullifies the benefits provided by physical activity." | 1.51 | Long-Term Moderate Exercise Combined with Metformin Treatment Induces an Hormetic Response That Prevents Strength and Muscle Mass Loss in Old Female Wistar Rats. ( Alarcón-Aguilar, A; Hernández-Álvarez, D; Hernández-Cruz, E; Ibañez-Contreras, A; Königsberg, M; Lazzarini-Lechuga, R; López-Cervantes, SP; López-Díazguerrero, NE; Luna-López, A; Mena-Montes, B; Morales-Salazar, A; Pedraza-Vázquez, G; Posadas-Rodríguez, P; Rosas-Carrasco, O; Santín-Márquez, R; Toledo-Pérez, R; Vázquez-Cárdenas, RR; Vilchis-DeLaRosa, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 8 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Rennie, KJ | 1 |
| Witham, M | 1 |
| Bradley, P | 1 |
| Clegg, A | 1 |
| Connolly, S | 1 |
| Hancock, HC | 1 |
| Hiu, S | 1 |
| Marsay, L | 1 |
| McDonald, C | 1 |
| Robertson, L | 1 |
| Simms, L | 1 |
| Steel, AJ | 1 |
| Steves, CJ | 1 |
| Storey, B | 1 |
| Wason, J | 1 |
| Wilson, N | 1 |
| von Zglinicki, T | 1 |
| Sayer, AAP | 1 |
| Lyu, Q | 1 |
| Wen, Y | 1 |
| He, B | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Sun, Y | 1 |
| Zhao, Y | 2 |
| Xu, L | 1 |
| Xiao, Q | 1 |
| Deng, H | 1 |
| Witham, MD | 1 |
| Granic, A | 1 |
| Pearson, E | 1 |
| Robinson, SM | 1 |
| Sayer, AA | 1 |
| Tezze, C | 1 |
| Amendolagine, FI | 1 |
| Nogara, L | 1 |
| Baraldo, M | 1 |
| Ciciliot, S | 1 |
| Arcidiacono, D | 1 |
| Zaramella, A | 1 |
| Masiero, G | 1 |
| Ferrarese, G | 1 |
| Realdon, S | 1 |
| Blaauw, B | 1 |
| Detienne, G | 1 |
| Beliën, AT | 1 |
| Sandri, M | 1 |
| Mercken, EM | 1 |
| Hernández-Álvarez, D | 2 |
| Mena-Montes, B | 2 |
| Toledo-Pérez, R | 2 |
| Pedraza-Vázquez, G | 2 |
| López-Cervantes, SP | 2 |
| Morales-Salazar, A | 1 |
| Hernández-Cruz, E | 1 |
| Lazzarini-Lechuga, R | 1 |
| Vázquez-Cárdenas, RR | 1 |
| Vilchis-DeLaRosa, S | 1 |
| Posadas-Rodríguez, P | 1 |
| Santín-Márquez, R | 1 |
| Rosas-Carrasco, O | 1 |
| Ibañez-Contreras, A | 1 |
| Alarcón-Aguilar, A | 1 |
| López-Díazguerrero, NE | 2 |
| Luna-López, A | 2 |
| Königsberg, M | 2 |
| Cui, M | 1 |
| Gang, X | 1 |
| Wang, G | 2 |
| Xiao, X | 1 |
| Li, Z | 1 |
| Jiang, Z | 1 |
| Chen, F | 2 |
| Xu, S | 1 |
| Wang, Y | 1 |
| Cao, L | 1 |
| Liu, T | 1 |
| Huang, T | 1 |
| Wei, Q | 1 |
| Ma, G | 1 |
| Wang, D | 1 |
| Massimino, E | 1 |
| Izzo, A | 1 |
| Riccardi, G | 1 |
| Della Pepa, G | 1 |
| Sánchez-Garibay, C | 1 |
| Long, DE | 1 |
| Peck, BD | 1 |
| Martz, JL | 1 |
| Tuggle, SC | 1 |
| Bush, HM | 1 |
| McGwin, G | 1 |
| Kern, PA | 1 |
| Bamman, MM | 1 |
| Peterson, CA | 1 |
| Zakeri, M | 1 |
| Fatemi, I | 1 |
| Kaeidi, A | 1 |
| Zakeri, MA | 1 |
| Hakimizadeh, E | 1 |
| Hassanipour, M | 1 |
| Rahmani, M | 1 |
| Hassanshahi, J | 1 |
| Ayoobi, F | 1 |
| Allahtavakoli, M | 1 |
| Cetrone, M | 1 |
| Mele, A | 1 |
| Tricarico, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Adults[NCT02308228] | Early Phase 1 | 109 participants (Actual) | Interventional | 2015-01-14 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Determine if metformin treatment augments strength gains in conjunction with progressive resistance training by one repetition maximum assessments. Maximum (1RM) leg extension muscle strength was assessed at week 4 (to account for neurological adaptations during the initial stages of the resistance program) and week 16. The percent change from week 4 to week 16 is reported. (NCT02308228)
Timeframe: Week 4 and week 16
| Intervention | Percent change (Mean) |
|---|---|
| Metformin | 15.3 |
| Placebo, Sugar Pill | 23.1 |
The ability of metformin to improve the hypertrophic response at the whole muscle level will be quantified by computed tomography. Percent change in normal density muscle area will be calculated as the difference between week 16 and week 0. (NCT02308228)
Timeframe: 16 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Metformin | 4.2 |
| Placebo, Sugar Pill | 10.5 |
To determine if metformin improves changes in body composition associated with progressive resistance training. Percent change in total body lean mass in kg was calculated as the difference between week 16 and week 0 from a total body DXA scan. (NCT02308228)
Timeframe: 16 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Metformin | 0.41 |
| Placebo, Sugar Pill | 1.95 |
The ability of metformin to improve the hypertrophic response to resistance training will be determined. Muscle biopsies of the vastus lateralis will be used to quantify myofiber cross-sectional area. The percent change in type 2 myofiber size between week 16 and week 0 was used. (NCT02308228)
Timeframe: 16 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Metformin | 18.5 |
| Placebo, Sugar Pill | 14.5 |
3 reviews available for metformin and Sarcopenia
| Article | Year |
|---|---|
Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia - A Narrative Review.
Topics: Aged; Animals; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Hypoglycemic Agents; Metformin | 2023 |
The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms.
Topics: Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Hand Strength; Humans; Hypoglycemic Age | 2021 |
Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II.
Topics: Age Factors; Aging; AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic A | 2014 |
2 trials available for metformin and Sarcopenia
| Article | Year |
|---|---|
MET-PREVENT: metformin to improve physical performance in older people with sarcopenia and physical prefrailty/frailty - protocol for a double-blind, randomised controlled proof-of-concept trial.
Topics: Aged; Double-Blind Method; Frailty; Humans; Metformin; Physical Functional Performance; Randomized C | 2022 |
Metformin to Augment Strength Training Effective Response in Seniors (MASTERS): study protocol for a randomized controlled trial.
Topics: Age Factors; Aged; Aging; Alabama; Clinical Protocols; Double-Blind Method; Female; Geriatric Assess | 2017 |
7 other studies available for metformin and Sarcopenia
| Article | Year |
|---|---|
The ameliorating effects of metformin on disarrangement ongoing in gastrocnemius muscle of sarcopenic and obese sarcopenic mice.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Fatty Acids, Nonesterified; Interl | 2022 |
A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia.
Topics: Aged; Aging; Animals; Galantamine; Humans; Infant; Metformin; Mice; Mice, Transgenic; Muscle, Skelet | 2023 |
Long-Term Moderate Exercise Combined with Metformin Treatment Induces an Hormetic Response That Prevents Strength and Muscle Mass Loss in Old Female Wistar Rats.
Topics: Age Factors; Animals; Female; Humans; Male; Metformin; Muscle Strength; Physical Conditioning, Anima | 2019 |
A cross-sectional study: Associations between sarcopenia and clinical characteristics of patients with type 2 diabetes.
Topics: Age Factors; Aged; Aged, 80 and over; Body Composition; Body Mass Index; China; Cross-Sectional Stud | 2020 |
Risk Factors for Sarcopenia in the Elderly with Type 2 Diabetes Mellitus and the Effect of Metformin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Exer | 2020 |
Metformin and tBHQ Treatment Combined with an Exercise Regime Prevents Osteosarcopenic Obesity in Middle-Aged Wistar Female Rats.
Topics: Animals; Bone Diseases, Metabolic; Female; Hydroquinones; Metformin; Obesity; Physical Conditioning, | 2021 |
Pro-neurocognitive and anti-sarcopenic benefits of one-year metformin therapy in ovariectomized aged mice.
Topics: Aging; Animals; Anxiety; Behavior, Animal; Brain; Cognition; Disease Models, Animal; Drug Administra | 2019 |